ES2266861T3 - Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina para el tratamiento de la obesidad. - Google Patents

Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina para el tratamiento de la obesidad. Download PDF

Info

Publication number
ES2266861T3
ES2266861T3 ES03762050T ES03762050T ES2266861T3 ES 2266861 T3 ES2266861 T3 ES 2266861T3 ES 03762050 T ES03762050 T ES 03762050T ES 03762050 T ES03762050 T ES 03762050T ES 2266861 T3 ES2266861 T3 ES 2266861T3
Authority
ES
Spain
Prior art keywords
group
compound
compound according
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03762050T
Other languages
English (en)
Spanish (es)
Inventor
Duane A. Burnett
Wen-Lian Wu
Thavalakulam K. Sasikumar
Martin S. Domalski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2266861T3 publication Critical patent/ES2266861T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03762050T 2002-06-27 2003-06-26 Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina para el tratamiento de la obesidad. Expired - Lifetime ES2266861T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
US391813P 2002-06-27

Publications (1)

Publication Number Publication Date
ES2266861T3 true ES2266861T3 (es) 2007-03-01

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03762050T Expired - Lifetime ES2266861T3 (es) 2002-06-27 2003-06-26 Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina para el tratamiento de la obesidad.

Country Status (14)

Country Link
US (1) US7109207B2 (enExample)
EP (1) EP1532147B1 (enExample)
JP (1) JP4522853B2 (enExample)
CN (1) CN100374440C (enExample)
AR (1) AR040344A1 (enExample)
AT (1) ATE334983T1 (enExample)
AU (1) AU2003258957A1 (enExample)
CA (1) CA2490531C (enExample)
DE (1) DE60307289T2 (enExample)
ES (1) ES2266861T3 (enExample)
MX (1) MXPA05000185A (enExample)
PE (1) PE20040749A1 (enExample)
TW (1) TW200401777A (enExample)
WO (1) WO2004002987A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
EP1601664B1 (en) * 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1867341A4 (en) * 2005-03-29 2009-07-29 Banyu Pharma Co Ltd THERAPEUTIC AGENT FOR NON-ALCOHOLIC FATBERS AND SCREENING METHODS FOR A DRUG-RELATED BIO-TREATMENT FOR THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATERS
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2072519A4 (en) * 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9090084B2 (en) 2010-05-21 2015-07-28 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
WO2001013917A1 (en) * 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE

Also Published As

Publication number Publication date
PE20040749A1 (es) 2004-10-23
CA2490531C (en) 2011-03-22
DE60307289D1 (de) 2006-09-14
JP2005535641A (ja) 2005-11-24
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
DE60307289T2 (de) 2007-10-18
CN1665812A (zh) 2005-09-07
CN100374440C (zh) 2008-03-12
EP1532147A1 (en) 2005-05-25
JP4522853B2 (ja) 2010-08-11
TW200401777A (en) 2004-02-01
HK1071567A1 (en) 2005-07-22
CA2490531A1 (en) 2004-01-08
MXPA05000185A (es) 2005-04-08
WO2004002987A1 (en) 2004-01-08
US20040024002A1 (en) 2004-02-05
EP1532147B1 (en) 2006-08-02
AU2003258957A1 (en) 2004-01-19
ATE334983T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
ES2333415T3 (es) Antagonistas de la mch basados en piperidina para el tratamiento de la obesidad y de trastornos del snc.
ES2241997T3 (es) Antagonistas de la mch y su uso en el tratamiento de la obesidad.
JP4643141B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
US6667319B2 (en) Neuropeptide Y Y5 receptor antagonists
US7157472B2 (en) Neuropeptide Y Y5 receptor antagonists
CA2490531C (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
WO2005021528A1 (en) 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
ES2305735T3 (es) Biariltetrahidroisoquinolin-piperidinas como antagonistas del receptor de mch selectivos, para el tratamiento de obesidad y trastornos relacionados.
ES2326980T3 (es) Aminobenzimidazoles utiles como antagonistas selectivos del receptor de la hormona concentrada de melamina (mch) para el tratamiento de la obesidad y desordenes asociados.
ES2327763T3 (es) Heterociclilos utilizados como antagonistas del receptor de la hormona concentrada de melanina para el tratamiento de la obesidad y trastornos relacionados.
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity